Insulin and steatonecrosis: Are they related?
John M. Amatruda, Arthur I. Salhanick – 1 December 1989 – Hepatic steatosis and steatonecrosis occur in non‐alcoholic individuals, usually in a setting of obesity, type II diabetes mellitus, and after jejunoileal bypass. We propose an hypothesis for the pathogenesis of these hepaic lesions based on an observation in peritoneal dialysis patients.
Tumor necrosis factor‐α induces a kB sequence‐specific DNA‐binding protein in human hepatoblastoma HepG2 cells
Ranjit Banerjee, Saul Karpen, Miriam Siekevitz, Gabriella Lengyel, Joachim Bauer, George Acs – 1 December 1989 – Tumor necrosis factor‐α is an inducer of acute‐phase protein synthesis in liver cells. The mechanism by which tumor necrosis factor‐α alters gene expression in these cells is largely unknown. In this study, we demonstrate that tumor necrosis factor‐α stimulates human immunodeficiency virus‐1 long terminal repeat‐promoted gene expression in the human hepatoblastoma HepG2 cell line and increased binding of trans‐activating factors to kappa B (kB) DNA sequences.
The kidney in liver disease. Edited by M. Epstein, 656 pp. Baltimore: Williams and Wilkins, 1988. $99.95
Neil A. Kurtzman – 1 November 1989
Animal models for alcoholic liver disease
Samuel W. French, H. Tsukamoto, Esteban Mezey – 1 November 1989
Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?
Denis J. Morgan, Richard A. Smallwood – 1 November 1989 – Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases. Galactose blood clearance, which may be taken as effective hepatic blood flow, decreased by approximately 30% in patients with cirrhosis (12.49 ± 0.76 ml/min/kg; mean ± SE; n = 17) compared with normal subjects (18.17 ± 1.03 ml/min/kg; n = 5).
Reduced‐size orthotopic liver transplantation: Use in the management of children with chronic liver disease
Jean C. Emond, Peter F. Whitington, J. Richard Thistlethwaite, Estella M. Alonso, Christoph E. Broelsch – 1 November 1989 – Reducing the size of a liver for use in a recipient smaller than the donor is one way to reduce mortality before orthotopic liver transplantation in children because of the scarcity of pediatric organ donors. In this report, we review the results of this approach over the past 2 years, during which we have used reduced‐size orthotopic liver transplantation routinely in small children.
Tissue‐specific activity of heterologous viral promoters in primary rat hepatocytes and Hep G2 cells
Fang Xian‐Jun, Armand Keating, Jean de Villiers, Morris Sherman – 1 November 1989 – In preparation for studies using gene transfer, we have identified transcriptional control elements which are active in primary rat hepatocytes. We used plasmids which were constructed so that the promoter or enhancer of interest initiated transcription of the bacterial chloramphenicol acetyltransferase (CAT) gene.
Augmentation of the natriuretic response to atrial natriuretic factor in cirrhosis
Alexander L. Gerbes – 1 November 1989 – The effects of atrial natriuretic factor (ANF) on splanchnic hemodynamics and renal function in portal hypertensive models are described incompletely. Furthermore, ANF‐induced vasodilatation and hypotension may limit the assessment of its own renal physiological effects. We infused ANF (human ANF 102‐126) to anesthetized portal vein‐ligated rats, a model with prehepatic portal hypertension. Arterial pressure was reduced by 17%, but portal pressure was unaffected.